Retatrutide in the UK

Retatrutide is one of the most searched-for compounds in the UK right now, and almost everything written about it online is either selling something or guessing. This guide sets out what is actually established: what the compound is, what stage of development it has reached, and exactly where it sits in UK law as of August 2026.

Research use only — not medical or legal advice. Retatrutide is an investigational compound, not an authorised medicine. Nothing here is guidance on human use, dosing or treatment, and it is not a recommendation to obtain or use it. If you are considering any weight-management treatment, speak to a GP or a registered pharmacist.

The short answer

Retatrutide is not approved anywhere in the world. It has no marketing authorisation from the MHRA in the UK, the FDA in the United States, or the EMA in the European Union. It cannot be lawfully prescribed as a licensed medicine, and it is not available from UK pharmacies.

It is not a controlled substance either — it is not scheduled under the Misuse of Drugs Act 1971. That combination is what creates the confusion: retatrutide is neither an approved medicine nor a banned drug. It occupies the same regulatory space as other research compounds, where the Human Medicines Regulations 2012 are the rule that matters.

What retatrutide is

Retatrutide, also known by its development code LY3437943, is a compound developed by Eli Lilly. It is described as a triple agonist: it acts on three receptors rather than one.

• GIP (glucose-dependent insulinotropic polypeptide) receptor
• GLP-1 (glucagon-like peptide-1) receptor
• Glucagon receptor

This three-receptor mechanism is what distinguishes it from earlier compounds in the same research area, which act on one or two of those targets. It is the reason retatrutide has attracted so much attention in metabolic research.

Where it is in development

Retatrutide is in Phase 3 clinical development under Eli Lilly's TRIUMPH programme — the final stage of trials before a company can apply for approval.

Eli Lilly has stated it intends to submit a Biologics Licence Application to the FDA in the first quarter of 2027. Standard FDA review takes roughly 10–12 months, or around 6 months if priority review is granted. That places the earliest realistic US approval somewhere in 2027 to 2028.

UK availability is a separate question again. Since Brexit, the MHRA grants UK marketing authorisations under its own authority, so a US or EU approval does not automatically make a medicine available in Britain. Retatrutide reaching UK pharmacies would require its own MHRA authorisation on its own timeline.

The practical takeaway: there is no lawful route to retatrutide as a medicine in the UK today, and there will not be one for some time.

What UK law actually says

Three things determine the position.

The Human Medicines Regulations 2012

This is the central rule. Any product sold or presented for treating, preventing or diagnosing a condition in people is a medicinal product, and supplying one without a marketing authorisation is unlawful. Retatrutide has no such authorisation. Selling it for human use, or marketing it with claims about weight loss or metabolic benefit, falls squarely inside this prohibition.

The Misuse of Drugs Act 1971

Retatrutide is not a scheduled controlled substance. Possessing it is not a drugs offence in the way possessing a Class A, B or C substance would be. This is frequently misunderstood — "not controlled" is not the same as "approved", and it does not make supply for human use lawful.

Advertising rules

Under the CAP Code, promoting a prescription-only or unlicensed medicine to the public is not permitted, and no medical claims may be made for an unauthorised product. This is why legitimate suppliers of research compounds describe what a compound is rather than what it might do for a person.

What "research use only" means here

Compounds that have not been authorised as medicines are supplied for in-vitro laboratory research — work done in controlled settings, on cells or in analytical apparatus, not in people.

That framing is not a formality or a disclaimer to be worked around. It is the distinction that determines whether a supply is lawful. A compound sold for research and used for research sits outside the medicines regime. The same compound sold or used for human consumption does not.

Why quality documentation matters more, not less, for unapproved compounds

An authorised medicine carries regulatory guarantees about identity, purity and manufacturing. An unapproved research compound carries none of them. Whatever is in the vial is whatever the supplier put there.

That is why any serious research supply should come with a batch-specific Certificate of Analysis recording identity and purity as measured by HPLC by the testing laboratory — not a generic document, and not a number copied from another lot. Without one there is no way to know what a material actually is.

We publish our COA library openly for exactly this reason, and our guide on what a Certificate of Analysis is explains what to look for on one.

Where MY PEPTIDES stands

We do not currently stock retatrutide. We have written this guide because it is one of the most misunderstood compounds in the UK market and the available information is poor, not because we are selling it.

Our catalogue is research peptides such as BPC-157, TB-500, GHK-Cu and CJC-1295, supplied for in-vitro laboratory research with a batch COA on every order. If that changes we will say so here.

The bottom line

Retatrutide is a genuine compound at a late stage of legitimate clinical development, and it may well become an approved medicine — but it is not one yet, in the UK or anywhere else. Anything offered for sale today is an unapproved research material, not a licensed treatment, and no lawful supplier can tell you otherwise.

If you are looking for weight-management treatment, the route is a GP or registered pharmacist and an authorised medicine, not an unapproved compound bought online.